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Abstract
Objectives To investigate the survival benefit of transarterial
chemoembolization (TACE) plus Iodine125 seed implanta-
tion (TACE-Iodine125) in hepatitis B-related HCC patients
with portal vein tumour thrombus (PVTT) and the underlying
prognostic factors.
Methods A retrospective matched cohort study was per-
formed on consecutive HCC patients with PVTT from
January 2011 to June 2014. Seventy patients (TACE-
Iodine125 group) who underwent TACE-Iodine125 were
compared with a historical case-matched control group of
140 patients (TACE group) who received TACE alone. The
survival of patients and the underlying prognostic factors were
analysed.
Results The median survival times of the TACE-Iodine125
and TACE groups were 11.0 and 7.5 months, respectively
(p<0.001). The survival probability at 12, 24, and 36 months
was 50 %, 14.5 %, and 14.5 % vs. 25 %, 9 %, and 5 % in the
TACE-Iodine125 and TACE groups, respectively (p<0.001).
The PVTT responders had better survival than the PVTT non-
responders (p<0.001). For the PVTT non-responders, there
were no differences in the survival curves between the groups
(p=0.353). Multivariate analysis showed that type III PVTT
(p<0.001) and APS (p<0.001) were independent predictors
of poor prognosis. In contrast, the treatment modality of
TACE-Iodine125 (p<0.001) and PVTT response (p=0.001)
were favourable prognostic features.
Conclusions TACE combined with Iodine125 seed implanta-
tion may be a good choice for selected HB-HCC patients with
PVTT.
Key Points
• TACE-Iodine125 was more effective than TACE for patients
with HCC-PVTT.
• The TACE-Iodine125 procedure was safe.
• TACE-Iodine125 was conditional for patients with HCC-
PVTT.
• TACE-Iodine125 resulted in a better PVTT response com-
pared to TACE alone.
• A good PVTT response is a favourable prognostic factor.
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Hepatocellular carcinoma (HCC) is the sixth most common
malignancy and the third leading cause of death of all malig-
nancies worldwide [1]. The majority of HCC in southern
China is related to hepatitis B (HB) [2]. Portal vein tumour
thrombus (PVTT) is a common complication of HCC that
occurs in approximately 10–40 % of HCC patients at the time
of diagnosis [3]. PVTT may cause diffuse intrahepatic metas-
tases and aggravate liver damage. PVTT has been proposed to
be the primal and independent predictor of poor prognosis in
HCC patients [4]. If untreated, HCC patients with PVTT
(HCC-PVTT) have a median overall survival (OS) of only
2.7–4 months, whereas patients without PVTT have a median
OS of 10–24 months [3].
Molecular targeted agents such as sorafenib were recom-
mended as the standard treatment for HCC and PVTT patients
[5, 6], and were shown to increase the median OS to
6.5 months in a phase III, randomized controlled trial in
Asia [7]. Regular application of sorafenib is limited in China
because many patients cannot afford the expensive cost.
Additionally, sorafenib is poorly tolerated in some patients,
as reflected by a discontinuation rate of 15–38 %, owing to
adverse events [7, 8]. InAsia, transarterial chemoembolization
(TACE) is still considered a useful treatment for patients with
unresectable HCC and PVTT [9]. Because the tumour-feeding
PVTT vessels mostly originate from the hepatic artery, TACE
for PVTT has proven to be effective, with a median survival
time of 7.1–9.5 months [10, 11]. However, the impact of
TACE alone on PVTT is limited because it is hard to
completely embolize the PVTT feeding vessels, and the re-
sponse to TACE is poor when PVTT is complicated with
arterial-portal-shunt (APS)[11, 12].
Studies have shown that HCC is radiosensitive [13].
Iodine125 seeds are an internal radiation source that have been
widely applied for the treatment of prostate cancer,head and
neck tumours and HCC [14, 15]. Iodine125 brachytherapy
alone showed promising efficacy for unresectable HCC with
PVTT [14]. We hypothesize that TACE and Iodine125 seed
implantation have synergistic effects on HCC with PVTT.
However, few reports have focused on the effects of combined
TACE and Iodine125 seed implantation (TACE-Iodine125)
for HCC with PVTT. In this study, we conducted a retrospec-
tive matched cohort study to evaluate the impact of TACE-
Iodine125 treatment on the long-term survival of hepatitis B-




From 1 January 2011, to 1 June 2014, 543 consecutive pa-
tients were diagnosed with HB-HCC with PVTT in two med-
ical centres: Lingnan Hospital and the Third Affiliated
Hospital of Sun Yat-sen University. A total of 160 cases treat-
ed with TACE combined with sorafenib and 30 cases treated
with sorafenib alone were excluded. Thus, 133 patients who
underwent TACE-Iodine125 and 220 patients who underwent
TACE alone were assessed for eligibility in the present study.
This retrospective matched cohort study was approved by the
local Ethics Committee. Informed consent was obtained from
all patients in this study.
Seventy patients from the pool of patients (n=133) treated
with TACE-Iodine125met the inclusion and exclusion criteria
and entered the TACE-Iodine125 group. The inclusion criteria
included: 1.) Positive test for the hepatitis B surface antigen
for 6 months; 2.) Medical imaging demonstrating type I or II
PVTT, non-obstructing type III PVTT, or obstructive type III
PVTTwith multiple collateral vessels; 3.) Child-Pugh class A
or B; and 4.) Eastern Cooperative Group performance status
(ECOG) score of 0–2. The exclusion criteria were: 1.)
Extrahepatic metastasis; 2.) Type IV PVTT; 3.) Hepatic en-
cephalopathy, severe ascites, oesophageal or gastric fundal
variceal bleeding or other serious medical comorbidities; 4.)
Patients complicated with hepatitis Avirus or hepatitis C virus
infection or other severe diseases; 5.) Patients who underwent
liver transplantation during this study; and 6.) Patients who
had malignant tumours in addition to HCC.
One hundred and forty patients were selected from the pool
of patients (n=220) treated with TACE alone and entered the
controlled group (TACE group). According to the principles
of the matched cohort study, the patients in the TACE group
were matched with the patients in the TACE-Iodine125 group
at a 1:2 ratio based on age (within 5 years) at TACE, gender,
baseline type of PVTT, Child-Pugh class (A or B), and BCLC
stage (stage C without extrahepatic metastasis).
HCC was diagnosed if the liver lesions (at least 1 cm in
diameter) in a hepatitis patient showed characteristic vascular
f e a t u r e s i n dynamic imag ing s t ud i e s : a r t e r i a l
hypervascularization with washout in the portal venous or
the late phase [16]. The presence of PVTTwas confirmed by
the observation of a low-attenuation intraluminal mass
expanding into the main portal vein and/or portal vein
branches with three-phase dynamic computed tomography
(CT) [17]. PVTT was categorized into four types according
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to the PVTT classification proposed by Shi et al. [18]: type I,
PVTT in segmental portal vein; type II, PVTT affecting
left/right portal vein; type III, PVTT affecting main portal
vein; and type IV, PVTT affecting superior mesenteric vein.
PVTT treatment strategy
For BCLC stage CHCC patients with PVTT, TACE-sorafenib
was recommended first if the main portal vein was patent or
multiple collateral vessels of the obstructed portal vein were
observed in the CT or magnetic resonance (MR) imaging.
Sorafenib was only recommended for patients with a
completely obstructed portal vein and absent collateral vessels
observed in the CT or MRI imaging. TACE-Iodine125 was
recommended for patients who refused TACE-sorafenib; oth-
erwise, TACE alone was performed for patients who refused
TACE-sorafenib and TACE-Iodine125, or had a contraindica-
tion for Iodine-125 seed implantation (prothrombin
time>17 seconds).
TACE procedure
The TACE procedure was performed as described previously
[19]. Briefly, TACE was performed when the tip of the
microcatheter was advanced into the hepatic segmental or
specific tumour-feeding artery. An emulsion of 2–20 mL of
lipiodol (Lipiodol Ultrafluido, Guerbet, Roissy, France) and
20–60 mg of doxorubicin hydrochloride were administered
into the feeding vessels, and a 50 mg solution of lobaplatin
(Hainan Changan International Pharmaceutical, China) was
infused into the hepatic artery. If the flow of the tumour-
feeding artery was still fast after the 20 ml upper limit was
reached, we used a gelatine sponge or polyvinyl alcohol par-
ticles to embolize the vessel until we could observe a signifi-
cantly sluggish flow. In patients with an arterioportal shunt
(APS), an embolization with 300–1000 μm polyvinyl alcohol
particles was performed to occlude the shunt via
superselective catheterization prior to infusion of the lipiodol
emulsion.
Iodine125 seed implantation
Iodine125 seed implantation into the PVTTwas conducted 7–
10 days after TACE when the results of the liver function tests
were comparable to those obtained before TACE. The
Iodine125 seeds were provided by the Beijing ZHIBO Bio-
Medical Technology Company, China. Each particle was
4.5 mm in length and 0.8 mm in diameter, with a radioactivity
of 0.6–0.8 mCi, radioactive half-life of 60.1 days, and radia-
tion energy of 27.4 KeV. Pre-procedural planning was con-
ducted using a three-dimensional conformal radiation therapy
treatment planning system (TPS) to determine the number of
Iodine125 seeds required, the target location for implantation,
the best percutaneous puncture site and the access route. The
targeted zone for implantation was the tumour thrombosis in
the segmental portal vein, left/right portal vein or main portal
vein. The prescription dose (PD) was set to 120 Gy.
Implantation was guided by CT, and the Iodine125 seeds were
implanted into the PVTT using 18 G needles and the implan-
tation gun that housed the Iodine125 seeds in the cartridge
chamber. Manual compression was applied to the percutane-
ous access site after the removal of the puncture needle.
Follow-up and retreatment
All patients were routinely followed up with contrast en-
hanced CT/MRI every 4–8 weeks after the first treatment.
The laboratory tests were conducted within one week before
and after the first TACE or Iodine125 seed implantation and
every 4–8 weeks during follow-up. At each visit, TACE was
repeated if the following criteria were reached: 1.) CT/MRI
imaging indicating viable tumour tissue at the original site or a
de novo neoplasm in the hepatic parenchyma; and 2.) Good
hepatic function reserve (Child-Pugh class A or B) and no
contraindication for TACE.
Treatment evaluation
All adverse events (AEs) were graded in accordance with the
Common Toxicity Criteria Adverse Events Version (CTCAE)
3.0. Mild subcapsular haemorrhage was defined as an asymp-
tomatic haemorrhage with clinically confirmed observations
not requiring intervention. All CT/MRI imaging evaluations
were conducted by two independent experienced radiologists.
The tumour response was assessed according to the modified
Response Evaluation Criteria in Solid Tumours (mRECIST)
[20]. The PVTT radiologic response was assessed as a com-
plete response (CR, complete disappearance), partial response
(PR, > 50 % decrease in the thrombus diameter), stable dis-
ease (SD, < 50 % decrease or<25 % increase in the thrombus
diameter or cavernous transformation), and progressive dis-
ease (PD, > 25 % increase in the thrombus diameter or newly
developed PVTT), based on the criteria described by Yoon
et al. [21]. The disease control rate was defined as the percentage
of CR, PR, or SD patients.
Power analysis
Sample sizes of 70 in the TACE-Iodine125 group and 140 in
the TACE group ensured at least 80 % power at a 5 % signif-
icance level to detect significant differences between the
groups when the hazard ratio of treatment over control was
0.58 or smaller for the log-rank test. For the Cox regression
analysis, these sample sizes ensured at least 80 % power at a
5 % significance to detect significant binary predictors if the
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adjusted hazard ratio was 0.55 and the r-square between this
factor and other factors in the model was 0.3 or less.
Statistical analysis
Quantitative data were reported as the mean±SD and compared
between two groups using Student’s t-test. Categorical data were
compared using the χ2 test. Survival was analysed using a
Kaplan-Meier curve and log-rank test. Overall survival (OS)
was defined as the period from the time of the first TACE pro-
cedure until death or the last follow-up. The Cox proportional
hazard model was used for univariate and multivariate analyses
to determine prognostic factors and the adjusted effect of the
TACE-Iodine125 group over the control. Factors significant at
the 0.20 level in the univariate analysis were chosen as candi-
dates for the multivariate analysis. The SPSS13.0 software
(SPSS, Chicago, IL, USA) for statistical analysis was used for
all analyses. Differences were deemed significant when p≤0.05.
Results
Baseline information and clinical outcome
The baseline demographic characteristics of patients were
shown in Table 1. There was no significant difference in the
baseline demographic characteristics between the TACE-
Iodine125 and TACE groups (p>0.05). The mean number
of TACE procedures performed over the study period was
3.3±1.7 (1–8) and 3.1±1.7 (1–8) for the TACE-Iodine125
and TACE groups, respectively. A radiologic response was
noted in 33 (1 CR, 16 PR and 16 SD, 47.1 %) cases in the
TACE-Iodine125 group (Fig. 1a–d) and 45 (0 CR, 20 PR and
25 SD, 32 %) cases in the TACE group, representing a signif-
icant difference (p=0.034). A PVTT radiologic response was
observed in 53 (0 CR, 38 PR and 15 SD, 76 %) cases in the
TACE-Iodine125 group and 69 (0 CR, 30 PR and 39 SD,
49 %) cases in the TACE group, representing a significant
different between the two groups (p<0.001). The numbers
of TACE procedures in the PVTT responders and PVTT
non-responders in the TACE-Iodine125 group were 3.3±1.6
(1–8) and 3.5±2.0 (2–7), respectively; there was no signifi-
cant difference between the groups (p=0.719).
Complications
The AEs of the two groups were detailed in Table 2. Grade 1
and 2 AEs were relatively mild and were alleviated spontane-
ously or after conservative management for only 5–7 days
post-procedure. Serious AEs (SAEs) such as biloma were
successfully managed by percutaneous puncture and draining.
No other SAEs were observed in either of the groups, and
there was no procedure-related mortality.
Survival
The mean and median follow-up times were 9.3±5.3 months
and 8.0 (3.6–43.0) months in the TACE-Iodine125 group and
8.4±5.9 months and 6.0 (3.5–37.0) months in the TACE group,
respectively. Altogether, 138 patients died during follow-up (28
in the TACE-Iodine125 group and 110 in the TACE group). The
median OS was 11 months in the TACE-Iodine125 group and
7.5 months in the TACE group. The 6-, 12-, 24-, and 36-month
survival rates were 85 %, 50 %, 14.5 %, and 14.5 % in the
TACE-Iodine125 group and 55 %, 25 %, 9 %, and 5 % in the
TACE group, respectively. The survival curves demonstrated
better outcomes in the TACE-Iodine125 group compared to
the TACE group (Fig. 2, p<0.001).
The survival times of type I and II PVTT patients were
significantly longer than type III PVTT patients (Fig. 3a,
p<0.001). Further analysis showed that better outcomes were
obtained for both type I + II and type III PVTT patients in the
TACE-Iodine125 group compared to the TACE group
(Fig. 3b and c, p=0.006 and p<0.001, respectively).
The OS of patients with a PVTT radiologic response was
better than the OS of patients who had no PVTT response
(Fig. 4a, p<0.001). For patients with no PVTT response, the
survival curves showed that there were no significant differ-
ences between the groups (Fig. 4b, p=0.353).
Univariate and multivariate analyses
Univariate COX model analysis was applied to the factors
involved in the preliminary screening. After screening, nine
factors were selected as candidates for multivariate analysis
(Table 3): treatment modality, PVTT type, PVTT response,
ECOG, level of HBV DNA, number of tumours, tumour size,
APS, and total bilirubin (TBIL). The multivariate Cox propor-
tional hazard model showed that type III PVTT [hazard Ratio
(HR)=0.310; 95 % confidence interval (CI): 0.212–0.453;
p<0.001], and APS (HR=2.137; 95 % CI: 1.441–3.170;
p<0.001) were associated with a poor prognosis. After adjust-
ment for these risk factors, the PVTT response (HR=0.503;
95 % CI: 0.338–0.748; p=0.001) and the treatment modality
of TACE-Iodine125 (HR= 0.359; 95 % CI: 0.22–0.571;
p < 0.001) were associated with a favourable prognosis
(Table 3) compared to TACE alone.
Discussion
Current treatment recommendations for HCC provide very
limited data on PVTT management. Despite the controversy,
TACE remains the first-line treatment for BCLC stage C HCC
patients in China. In the present study, all HCC participants
successfully received TACE treatment without serious com-
plications (i.e., TACE-related liver failure). Notably, the
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following steps were crucial for the performance of TACE for
HCC-PVTT patients in this study. First, the careful selection
of qualified patients was crucial for the success of TACE.
Only patients with CHILD-PUGHA/B and ECOG 0-2 whose
blood supply in the main portal vein was normal or incom-
pletely disrupted or had imaging-confirmed portal-collateral
circulation were indicated for TACE in our study. Second, all
TACE procedures were carefully performed with a
superselective catheterization technique. For patients with
PVTT, some studies have also shown that using less aggres-
sive embolization after superselective catheterization is safe,
with no increase in morbidity or mortality [22, 23].
Table 1 Baseline characteristics







Age, year 51.1 ± 11.1 (28 ~ 80) 51.6 ± 10.8 (22 ~ 81) 0.748
Sex (M/F) 63/7 127/13 0.868
Type of PVTT (I+II/III) 41/29 82/58 1.000
APS (+/-) 20/50 39/101 0.914
Child-Pugh class (A/B) 0.558
A (A5, A6) 31 (15,16) 68 (35, 33)
B (B7, B8, B9) 39 (27,9,3) 72 (54,16,2)
ECOG (0/1 + 2) 41/29 79/61 0.767
Tumor size (cm), <7/≥7 39/31 83/57 0.621
Number of Tumor, <3/≥3 30/40 70/70 0.329
AFP level (ng/ml), <400/≥400 31/39 59/81 0.767
HBV DNA (IU/ml), <104/≥104 39/31 64/76 0.172
ALT, U/L 71.5 ± 32.6 71.2 ± 39.3 0.951
GGT, U/L 168.7 ± 54.0 157.4 ± 52.9 0.149
Albumin, g/L 36.1 ± 3.3 35.7 ± 2.9 0.353
TBIL, umol/L 15.9 ± 7.4 16.3 ± 7.6 0.683
Creatinine, umol/L 67.9 ± 14.7 65.3 ± 16.9 0.261
Platelet count, 109/L 118.6 ± 67.4 126.8 ± 55.1 0.345
Hemoglobin, g/L 124.0 ± 12.2 121.6 ± 14.8 0.235
White blood cell, 109/L 4.70± 1.05 4.61 ± 0.90 0.529
Fig. 1 Male, 57 years old, BCLC
C stage HCC. (a) Contrast
enhanced CT cross sectional
image demonstrating a HCC
lesion in segment 6 and PVTT
reaching the main portal vein
(white arrow). (b) Angiogram
from the celiac trunk
demonstrating the plexiform
feeding artery of PVTT and APS
(black arrow). (c) CT-guided
Iodine125 seed implantation in
PVTT. (d) CT images acquired
28 months after the initial
treatment demonstrate no viable
tumour and the disappearance of
PVTT and the patent portal vein
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Although TACE has been proven to be an effective and
safe basic therapeutic method for intrahepatic primary HCC
lesions, combined treatment with TACE and novel drugs or
other therapies might be a better alternative strategy for HCC
with PVTT. TACE combined with sorafenib was considered
to be an effective combination treatment for HCC-PVTT [24]
and was first recommended by the attending physician in our
institute if the main portal vein was patent or multiple collat-
eral vessels from the obstructed portal vein were observed in
the CTor MRI imaging [19]. Nevertheless, sorafenib does not
represent a cost-effective drug in this indication in some de-
veloping countries [25]. Additionally, some patients are afraid
of a deterioration of their quality of life owing to drug-induced
side effects, and consequently refuse to take sorafenib. In this
study, althoughwe recommended that all HCC-PVTT patients
take sorafenib as a standard treatment, these patients refused
for the above reasons and consented to TACE alone or TACE
plus Iodine125 seed implantation.
There is increasing evidence that Yttrium-90 radioactive
microsphere hepatic artery embolization (TARE) can be deliv-
ered safely and effectively in HCC-PVTT patients, leading to a
median OS of approximately 10 months following the proce-
dure [26]. TARE might have an advantage over TACE in
Child-Pugh A patients with very large tumours where TACE
does not provide a very effective treatment [27]. Similar to
Yttrium-90, Iodine131 is another β-emitter with a physical
half-life of 8.05 days that can be used as a radionuclide therapy
for HCC and PVTT. Because Iodine131-lipiodol is a noparticle
embolization at the end of the procedure, PVTT is not consid-
ered to be a relative or absolute contraindication for Iodine131-
lipiodol. Although most studies have failed to demonstrate any
survival benefits, Iodine131-lipiodol seems to be much better
tolerated than chemoembolization, both in terms of clinically
expressed side effects and arteriographic findings [28]. Lintia-
Gaultier et al [29] reported a median survival of 32 weeks in
fifty patients (86 % of them complicated with PVTT) treated
with Iodine131-lipiodol compared with 8 weeks in the untreat-
ed group. Raoul et al. [30] reported a similar result of a median
survival of 6 months in the Iodine131-lipiodol group compared
with 1.5 months in the control group for Child-Pugh A and B
patients with PVTT. However, the treatment tolerance and ef-
fectiveness of radioembolization or Iodine131-lipiodol may be
Table 2 The adverse effects of
two groups in accordance with the
Common Terminology Criteria
for Adverse Events version 3.0
Groups All Grade Grade 1–2 Grade3 or Higher levels p value
Fever 0.419
TACE-I125 56 (80.0 %) 56 (80.0 %) 0
TACE 105(75.0 %) 105 (75.0 %) 0
Abdominal pain 0.099
TACE-I125 63 (90.0 %) 63 (90.0 %) 0
TACE 98 (70.0 %) 98 (70.0 %) 0
Nausea and/or vomiting 0.518
TACE-I125 41 (58.6 %) 41 (58.6 %) 0
TACE 77 (55.0 %) 77 (55.0 %) 0
Subcapsular hemorrhage of liver 0.008
TACE-I125 3 (4.3 %) 3 (4.3 %) 0
TACE 0 0 0
Biloma 0.477
TACE-I125 4 (5.7 %) - 4 (5.7 %)
TACE 5 (3.6 %) - 5 (3.6 %)
ALT, AST and/or TBIL Increased 1.000
TACE-I125 70 (100 %) 70 (100 %) 0
TACE 140 (100 %) 140 (100 %) 0
Fig. 2 Kaplan-Meier estimates of OS between the TACE-Iodine125 and
TACE groups
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affected when it is used for cirrhotic patients or patients with
APS or arterio-venous shunts (AVS) [31]. Three-dimensional
conformal radiation therapy (3-DCRT) is another novel radio-
therapy for PVTT [13]. Tang et al. [32] reported that combined
TACE and 3-DCRT resulted in a median survival time of
12.3 months and survival rates of 51.6 %, 28.4 %, and
19.9 % at 1, 2, and 3 years, respectively, among 185 HCC-
PVTT cases. However, no prospective study has compared
Iodine-131-lipiodol, TARE, 3-DCRT and Iodine-125 seed im-
plantation in HCC patients with PVTT.
Yang et al. [33] adopted a strategy of TACE combined with
intravascular implantation of Iodine125 seed strands into the
portal vein for the treatment of 43 HCC-PVTT patients and
reported that the average and median survival times were
221.7 ± 16.3 days and 210.0 ± 17.5 days, respectively.
However, the potential problem associated with the intravas-
cular implantation of radioactive seed strands is that insuffi-
cient irradiation of PVTT may occur due to the uneven distri-
bution of the Iodine125 seed strand radioactive sources inside
the PVTT. Based on the pre-procedural TPS planning and CT
scan surveillance during the procedure, percutaneous
transhepatic puncture of the PVTT and implantation of
Iodine125 seeds inside and around the PVTT could allow an
even and quantifiable distribution of the radioactive source.
Our results showed that the OS of patients who had a ra-
diologic response to PVTTwas more favourable than patients
who had no response to PVTT. There were no significant
differences in the survival of patients with no response to
PVTT between the TACE-I125 and TACE groups. Our results
indicated that the separate treatment of PVTTwas very impor-
tant for prolonging the survival time of patients with HCC and
PVTT. We speculate that the effective treatment of PVTT can
partially or completely reopen the portal venous system,
which can in turn maintain the oxygen supply to the liver,
induce a good state of liver function, and effectively reduce
the incidence of portal hypertension-related complications.
Additionally, effective PVTT treatment can also prevent or
delay intrahepatic metastasis and tumour recurrence.
APS was considered to be another independent predictor of
poor prognosis and a typical complication of PVTT [12, 34].
Although the exact reason was unknown, some studies found
that APS could be decreased or cured with radiotherapy [31].
However, future studies are required to prove that Iodine125
implantation in the PVTT can lead to a good APS response.
Fig. 3 Kaplan-Meier estimates of (a) OS between type I + II and III PVTT patients, (b) OS between the TACE-Iodine125 and TACE groups in type I + II
PVTT patients, and (c) OS between the TACE-Iodine125 and TACE groups in type III PVTT patients
Fig. 4 Kaplan-Meier estimates of
(a) OS between PVTT responders
and non-responders and (b) OS
between PVTT non-responders in
the TACE-Iodine125 and TACE
groups
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Some studies showed that Child-Pugh B patients had signif-
icantly poorer survival compared to Child-Pugh A patients [35].
This present study did not demonstrate a favourable survival
benefit in Child-Pugh A compared with Child-Pugh B patients,
whichmay be related to the fact that the 81 (73%) Child-Pugh B
patients in this study had a Child-Pugh numeric score of 7 (B7).
A previous study demonstrated that Child-Pugh B7 patients had
a larger survival rate than Child-Pugh B8 and B9 patients [36].
Piscaglia et al. [36] reported that Child-Pugh B7 HCC patients
achieved an acceptable median survival of 22.0 months (range
0–60.0) after TACE. That result was comparable to the results
included in Llovet’s meta-analysis [37], which was largely based
on Child-Pugh A patients. In another retrospective study by
Federico et al. [38], the OS in Child-Pugh A patients was not
significantly different compared to Child-Pugh B7 patients.
Future trials should validate this observation.
The main limitation of retrospective studies is selection bias.
To reduce bias caused by using the TACE group as the control,
the factors most likely to affect the survival outcome were used
as matching factors to select a matching cohort of patients.
However, the retrospective nature of the study dictated that se-
lection bias was unavoidable. A randomized clinical trial is re-
quired to validate the findings from this study. Furthermore, only
patients with HB-HCC were studied here. Thus, the results from
this study may not be applicable to other HCC populations.
In conclusion, combined treatment with TACE and
Iodine125 seed implantation achieved a promising OS in se-
lected unresectable HB-HCC patients with PVTT. Therefore,
TACE combined with Iodine125 seed implantation might be
an alternative treatment for these patients. A randomized clin-
ical trial is warranted to validate the findings of this study.
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